Johnson Fistel Announces Class Action Lawsuit Against Lantheus Holdings, Inc. (LNTH) on Behalf of Investors GlobeNewswire October 17, 2025 DENVER, Oct. 17, 2025 (GLOBE NEWSWIRE) — Johnson Fistel, PLLP announces that a class action lawsuit has commenced on behalf of investors of Lantheus Holdings, Inc. (NASDAQ: LNTH). The lawsuit seeks to recover losses on behalf […]
(NYSE:VFC), SAN DIEGO, Oct. 17, 2025 (GLOBE NEWSWIRE) — Johnson Fistel, PLLP's Denver office announces that a class action lawsuit has been filed on behalf of investors who purchased V.F. Corporation (NYSE: VFC) securities between October 30, 2023, and May 20, 2025. Investors who suffered losses during this period may be eligible for compensation. Eligibility
V.F. Corporation (VFC) Class Action Lawsuit Announced by Johnson Fistel GlobeNewswire October 17, 2025 SAN DIEGO, Oct. 17, 2025 (GLOBE NEWSWIRE) — Johnson Fistel, PLLP's Denver office announces that a class action lawsuit has been filed on behalf of investors who purchased V.F. Corporation (NYSE: VFC) securities between October 30, 2023, and May 20, 2025.
The globalPOP Treatment and Management / Pelvic Organ Prolapse Market, valued at US$0.72 billion in 2024, stood at US$0.77 billion in 2025 and is projected to advance at a resilient CAGR of 6.6% from 2025 to 2030, culminating in a forecasted valuation of US$1.06 billion by the end of the period. POP Treatment and Management
MetroCity Bankshares, Inc. (“MetroCity” or the “Company”) (NASDAQ: MCBS), holding company for Metro City Bank (the “Bank”), today reported net income of $17.3 million, or $0.67 per diluted share, for the third quarter of 2025, compared to $16.8 million, or $0.65 per diluted share, for the second quarter of 2025, and $16.7 million, or $0.65
Potential first-in-class, and industry-leading DNA polymerase Theta (Polθ) inhibitor, ART6043 demonstrated an attractive tolerability profile, expected PK/PD activity, and promising clinical signals Results support the potential advancement of ART6043 into Phase 2 clinical development CAMBRIDGE, United Kingdom and NEW YORK, October 17, 2025 – Artios Pharma Limited (“Artios”), a biopharmaceutical company committed to realizing the
Artios Announces Phase 1/2a Data for DNA Polymerase Theta Inhibitor ART6043 at ESMO Congress 2025 GlobeNewswire October 17, 2025 Potential first-in-class, and industry-leading DNA polymerase Theta (Polθ) inhibitor, ART6043 demonstrated an attractive tolerability profile, expected PK/PD activity, and promising clinical signals Results support the potential advancement of ART6043 into Phase 2 clinical development CAMBRIDGE, United
Indoor Location Market Surges to $31.4 billion by 2029 – Dominated by Cisco (US), Google (US), Microsoft (US) GlobeNewswire October 17, 2025 Delray Beach, FL , Oct. 17, 2025 (GLOBE NEWSWIRE) — According to MarketsandMarkets(TM), the Indoor Location Market to grow from USD 11.9 billion in 2024 to USD 31.4 billion by 2029, at a
NEW YORK CITY, NY / ACCESS Newswire / October 17, 2025 / NEW YORK, NY / ACCESS Newswire / October 17, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of MoonLake Immunotherapeutics ("MoonLake") (NASDAQ:MLTX) concerning possible violations of federal securities laws. On September 29, 2025, MoonLake announced that its experimental
TORONTO, ON, Oct. 17, 2025 (GLOBE NEWSWIRE) — For immediate release With the imminent return of the Ontario Legislature, students and workers are sending a final message to the government: reject Bill 33. The Canadian Federation of Students-Ontario (CFS-O) represents 350,000 post-secondary students across Ontario alongside the Ontario Public Service Employees Union (OPSEU), the Ontario